Clinical trial · Observational
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
A Single-center, Prospective Cohort Study of Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was withdrawn before participant enrollment because the research team decided not to initiate the study after reassessing its feasibility.
Summary
Brief summary (as posted)
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Refractory Colorectal Carcinoma | Colorectal Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fruquintinib Combined With TAS-102 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Fru plus TAS-102
- description
- mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line
- interventionNames
- Drug: Fruquintinib Combined With TAS-102
Primary outcomes (2)
- measure
- Progression-free Survival (PFS)
- timeFrame
- 3 years
- description
- PFS was calculated from the date of fruquintinib administration to the first observation of disease progression or death.
- measure
- Overall Survival (OS)
- timeFrame
- 3 years
- description
- OS was defined as the time from fruquintinib administration to death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histology-confirmed metastatic CRC (mCRC) * Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab * Fruquintinib administered as salvage treatment * Age: 18-75 years old * Informed consent Exclusion Criteria: * Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy * Fruquintinib and/or TAS-102 administration as second-line treatment * Drug administration stopped after less than two cycles
References
Publications (0)
Data not yet available